Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ACXP with free AI briefings, catalyst countdowns, and dilution alerts.

ACXP · Acurx Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$9.7M Cash on Hand
13.8mo Cash Runway
Follow ACXP by email Get an email when ACXP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ACXP, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Ibezapolstat Clostridium Difficile Infection Recurrence Phase 2 · NCT07513285 Recruiting
Vancomycin Clostridium Difficile Infection Phase 2 · NCT04247542 Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ACXP holds $9.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.1M/quarter from operations, an estimated runway of 13.8 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 63 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ACXP files for a raise →

👥 Who Owns ACXP

Insiders 45.2% Institutions (20 holders) 3.9% Public and other holders 50.9%
HolderTypeShares% of sharesAs of
David P Luci
President and CEO, Director · +586,361 options
Insider 1,147,541 21.78% 2025-01-06
Robert J Deluccia
Director · +586,361 options
Insider 1,014,043 19.24% 2025-01-06
Carl Sailer
Director · +38,781 options
Insider 142,183 2.70% 2025-01-06
Joseph C Scodari
Director · +38,781 options
Insider 27,708 0.53% 2025-01-06
Jack H Dean
Director · +24,002 options
Insider 27,546 0.52% 2025-01-06
James J. Donohue
Director · +24,002 options
Insider 22,352 0.42% 2025-01-06

Share count 5,269,921 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ACXP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ACXP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.